Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, Observe changes in patients' biochemical and imaging indicators, liver stiffness values, fecal microbiota, and metabolites before and after the use of sulfasalazine.

NCT Number	NCT06293378
Lead Sponsor	The Second Affiliated Hospital of Chongqing Medical University
Conditions	Cirrhosis, Liver, Fibrosis, Liver
Enrollment	330 participants
Start Date	2024-02-01
Primary Completion	2028-10-10 (estimated)
Study Completion	2028-10-10 (estimated)
Updated on ClinicalTrials.gov	2025-02-20